Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism
The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availability, relatively high spatiotemporal resolution, and the ability to map function over the entire brain. Thus, BOLD fMRI is the most widely applied technology to study healthy brain function and pathophysiology associated with disease. In studies of drug abuse and psychiatric illness though, normal assumptions mapping BOLD signals to neurometabolism may be violated. Generally, these effects are ignored, resulting in large study-to-study variability.
Quantitative fMRI (qfMRI) measures metabolism directly and is more suitable for studies of drug abuse and psychiatric illness. However, qfMRI is too complex for routine use. Cerebral metabolism during brain activation during visual stimulation measured with a new fMRI approach that is simple enough for clinical applications will be compared to CMRO2 activation measured using standard qfMRI.
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems|
- Changes in brain activity associated with visual stimulation [ Time Frame: cross-sectional, start and up to 6 minutes ] [ Designated as safety issue: No ]CMRO2 brain activation in visual cortex associated with visual stimulation
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||January 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
No intervention. Participants are scanned at baseline.
Healthy subjects will undergo a single imaging session. During the imaging session, fMRI and simultaneous near-infrared spectroscopy measurements will be made during visual stimulation (e.g., viewing a flashing checkerboard). This is a methods development study focused on comparing a new method for estimating CMRO2 associated with brain activation with the standard fMRI approach for estimating CMRO2.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01825096
|United States, Massachusetts|
|McLean Imaging Center||Recruiting|
|Belmont, Massachusetts, United States, 02478|
|Contact: Stacey Farmer, BA 617-855-2359 firstname.lastname@example.org|
|Principal Investigator: Lisa D Nickerson, PhD|
|Principal Investigator:||Lisa D Nickerson, PhD||Mclean Hospital|